TY - JOUR
T1 - Dopaminergic alterations in populations at increased risk for psychosis
T2 - A systematic review of imaging findings
AU - van Hooijdonk, Carmen F. M.
AU - Drukker, Marjan
AU - van de Giessen, Elsmarieke
AU - Booij, Jan
AU - Selten, Jean-Paul
AU - van Amelsvoort, Therese A. M. J.
N1 - Funding Information: The authors would like to thank Deniz Keskinel (DK) and Annemarie Westermann (AW) for their contribution to the review. Publisher Copyright: © 2022 The Authors
PY - 2022/6/1
Y1 - 2022/6/1
N2 - Alterations of the dopaminergic system may be important neurobiological correlates of vulnerability and transition to psychosis. We systematically reviewed the evidence for dopaminergic alterations demonstrated by in-vivo imaging studies in humans at increased risk of developing psychosis, covering clinical, genetic, and environmental high-risk groups. All 63 included studies utilized Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), or neuromelanin-sensitive Magnetic Resonance Imaging (NM-MRI) methods to collect data concerning the dopaminergic system during rest and/or following pharmacological, behavioural, or cognitive challenges. The current evidence highlights that 1) striatal dopamine D2/3 receptor availability is unaltered in all three high-risk groups compared with healthy individuals; 2) striatal dopamine synthesis capacity (sDSC) is increased in some clinical and genetic high-risk individuals relative to controls (e.g. people that meet clinical criteria for being at ultra-high risk of developing psychosis and individuals with 22q11.2 deletion syndrome), while sDSC is decreased in cannabis-using environmental high-risk individuals. It seems likely that all three high-risk groups can be stratified into multiple subgroups, with varying risks to develop psychosis, transition rates, and underlying neurobiology. The present results support the hypothesis that dopaminergic abnormalities occur before high-risk individuals develop psychosis.
AB - Alterations of the dopaminergic system may be important neurobiological correlates of vulnerability and transition to psychosis. We systematically reviewed the evidence for dopaminergic alterations demonstrated by in-vivo imaging studies in humans at increased risk of developing psychosis, covering clinical, genetic, and environmental high-risk groups. All 63 included studies utilized Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), or neuromelanin-sensitive Magnetic Resonance Imaging (NM-MRI) methods to collect data concerning the dopaminergic system during rest and/or following pharmacological, behavioural, or cognitive challenges. The current evidence highlights that 1) striatal dopamine D2/3 receptor availability is unaltered in all three high-risk groups compared with healthy individuals; 2) striatal dopamine synthesis capacity (sDSC) is increased in some clinical and genetic high-risk individuals relative to controls (e.g. people that meet clinical criteria for being at ultra-high risk of developing psychosis and individuals with 22q11.2 deletion syndrome), while sDSC is decreased in cannabis-using environmental high-risk individuals. It seems likely that all three high-risk groups can be stratified into multiple subgroups, with varying risks to develop psychosis, transition rates, and underlying neurobiology. The present results support the hypothesis that dopaminergic abnormalities occur before high-risk individuals develop psychosis.
KW - At-risk
KW - Dopamine
KW - Neuroimaging
KW - Psychosis
UR - http://www.scopus.com/inward/record.url?scp=85127309081&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.pneurobio.2022.102265
DO - https://doi.org/10.1016/j.pneurobio.2022.102265
M3 - Review article
C2 - 35351599
SN - 0301-0082
VL - 213
JO - Progress in Neurobiology
JF - Progress in Neurobiology
M1 - 102265
ER -